RespireRx Pharmaceuticals subsidiary ResolutionRX signs on iNGENu as CRO for dronabinol development

–News Direct–

RespireRX Pharmaceuticals chief financial officer Jeff Margolis joins Proactive's Natalie Stoberman with the news that subsidiary ResolutionRX has announced a services agreement with Australian contract research organization (CRO) iNGENu.

Margolis said iNGENu will act as a full-service CRO in support of ResolutionRx’s research and development program, which is developing a proprietary formulation of dronabinol for the treatment of obstructive sleep apnea and anorexia.

Contact Details

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/respirerx-pharmaceuticals-subsidiary-resolutionrx-signs-on-ingenu-as-cro-for-dronabinol-development-418005608